Ondine Biomedical Recognized as Finalist in PwC Canada’s Vision to Reality (#V2R) Awards

TORONTO, ON and VANCOUVER, BC  – Mar. 29, 2019

PwC Canada today announced Ondine Biomedical Inc. as a finalist in The Visionary category in this year’s Vision to Reality (V2R) Awards. The Vision to Reality (V2R) Awards is PwC Canada’s annual program aimed at recognizing and celebrating the most forward-thinking organizations in Canada.  To learn more: www.pwc.com/ca/v2r

Ondine was nominated for its breakthrough and life-saving technology, Photodisinfection, a patented, light-activated antimicrobial system that kills bacteria, viruses, and fungi—including superbugs—of all kinds in minutes without the use of antibiotics. Ondine’s technology has been deployed for several years in hospitals in British Columbia, preventing significant numbers of surgical site infections which would otherwise have resulted in patient morbidity, mortality and millions of dollars of unnecessary annual cost.

Ondine’s technology directly targets the global threat of multidrug resistance. Identified by the World Health Organization as one of the top five human health crises, multidrug-resistant infections are forecasted to cause a staggering 10 million deaths and US$100 trillion economic impact annually by 2050 – more than cancer, diabetes, cholera and measles combined.

“The Ondine team is passionate about improving patient outcomes with our non-antibiotic, topical technology for treatment and prevention of multidrug resistant infections. We are honored to be recognized by PwC for our unique approach to addressing this global health issue,” said Carolyn Cross, Chairman and CEO. “We would like to thank PwC for its recognition and support of Canadian innovation.”

“We’re thrilled to recognize our V2R Awards finalists who represent innovators of all sizes and industries. Selected by the independent panel of judges, the finalists demonstrate that innovation is thriving across every region in Canada,” says Chris Dulny, Chief Innovation Officer, PwC Canada. “The Awards celebrate some of the country’s best innovators and bring together a network of leaders to collaborate and share ideas. Ultimately, this type of collaboration helps make Canada a more competitive place for innovation and we’re proud to be a part of that.”

About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Vancouver based company dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine’s antimicrobial program utilizes a platform technology called Photodisinfection, a light-activated approach developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance.

Ondine’s flagship universal nasal Photodisinfection has been deployed at leading Canadian hospitals for several years, where it has helped prevent hundreds of post-surgical infections and saved the facilities millions of dollars annually. A recent abstract was published which found that the impact on post spine surgery infections at Vancouver General Hospital over a period of eight years was highly significant. The results showed a 78% reduction in surgical site infection rate and found one infection was prevented for every 18 patients treated. $4.24 million was saved annually, and no adverse events were reported. As a result, nasal Photodisinfection is being recommended for routine use in all spine surgeries in Canada.

Other applications of the Photodisinfection platform are under development, including Sinuwave (TM), a Photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube Photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia.

Contact
Ondine Biomedical Inc.
www.ondinebio.com
Angelika Vance | 1.604.838.2702 | avance@ondinebio.com

Share this post via Email
Share this post on Twitter
Share this post on LinkedIn
Print PDF of this post